Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 3 4 2009 12 01 43 45 Fatemeh Nadali Pathology Department, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran Sh Ferdowsi School of Allied Health Sciences, Tehran University of Medical Sciences, Tehran, Iran P Karimzadeh School of Allied Health Sciences, Tehran University of Medical Sciences, Tehran, Iran Bahram Chahardouli Hematology-Oncology and BMT Research Center, Shariati Hospital, Tehran University of Medical Science, Tehran, Iran N Einollahi School of Allied Health Sciences, Tehran University of Medical Sciences, Tehran, Iran SA Mousavi Hematology-Oncology and BMT Research Center, Shariati Hospital, Tehran University of Medical Science, Tehran, Iran Babak Bahar Hematology-Oncology and BMT Research Center, Shariati Hospital, Tehran University of Medical Science, Tehran, Iran H Dargahi School of Allied Health Sciences, Tehran University of Medical Sciences, Tehran, Iran Kamran Alimoghaddam Hematology-Oncology and BMT Research Center, Shariati Hospital, Tehran University of Medical Science, Tehran, Iran Ardeshir Ghavamzadeh Hematology-Oncology and BMT Research Center, Shariati Hospital, Tehran University of Medical Science, Tehran, Iran SH Ghaffari Hematology-Oncology and BMT Research Center, Shariati Hospital, Tehran University of Medical Science, Tehran, Iran 2015 10 01 JAK2 is a tyrosine kinase that plays an important role in the signaling pathways of many hematopoietic growth factor receptors. A single acquired point mutation – V617F – in JAK2 occurs in the great majority of patients with polycythemia vera (PV) and approximately half of the patients with idiopathic myelofibrosis (IMF) or essential thrombocythemia (ET). In contrast, the JAK2-V617F mutation is only rarely found in chronic myeloid leukemia (CML) but, recently, some authors have reported the coexistence of JAK2V617F and BCR/ABL+ in CML patients expressing the p210 BCR–ABL oncoprotein. Here, we report a CML patient with the expression of p210/b2a2 type BCR–ABL transcript and JAK2V617F mutation. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/230 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/230/223